Journal of Molecular Graphics and Modelling, Год журнала: 2024, Номер 131, С. 108809 - 108809
Опубликована: Июнь 13, 2024
Язык: Английский
Virology Journal, Год журнала: 2022, Номер 19(1)
Опубликована: Окт. 9, 2022
Most COVID-19 patients recovered with low mortality; however, some experienced long-term symptoms described as "long-COVID" or "Post-COVID syndrome" (PCS). Patients may have persisting for weeks after acute SARS-CoV-2 infection, including dyspnea, fatigue, myalgia, insomnia, cognitive and olfactory disorders. These last months in patients. PCS progress association the development of mast cell activation syndrome (MCAS), which is a distinct kind disorder, characterized by hyper-activation cells inappropriate excessive release chemical mediators. survivors, mainly women, persistent severe fatigue 10 recovery history neuropsychiatric disorders are more prone to develop PCS. High D-dimer levels blood urea nitrogen were observed be risk factors associated pulmonary dysfunction survivors 3 post-hospital discharge has systemic manifestations that resolve time no further complications. However, final outcomes chiefly unknown. Persistence inflammatory reactions, autoimmune mimicry, reactivation pathogens together host microbiome alterations contribute The deregulated mediators MCAS produces extraordinary during course infection correlated severity Therefore, treated antihistamines, inhibition synthesis mediators, mediator release, degranulation cells.
Язык: Английский
Процитировано
93
Signal Transduction and Targeted Therapy, Год журнала: 2023, Номер 8(1)
Опубликована: Ноя. 10, 2023
Abstract Proper subcellular localization is crucial for the functioning of biomacromolecules, including proteins and RNAs. Nuclear transport a fundamental cellular process that regulates many macromolecules within nuclear or cytoplasmic compartments. In humans, approximately 60 are involved in transport, nucleoporins form membrane-embedded pore complexes, karyopherins cargoes through these Ran system ensure directed rapid transport. Many play additional essential roles mitosis, biomolecular condensation, gene transcription. Dysregulation linked to major human diseases such as cancer, neurodegenerative diseases, viral infections. Selinexor (KPT-330), an inhibitor targeting export factor XPO1 (also known CRM1), was approved 2019 treat two types blood cancers, dozens clinical trials ongoing. This review summarizes three decades research data this field but focuses on structure function individual from recent studies, providing cutting-edge holistic view role health disease. In-depth knowledge rapidly evolving has potential bring new insights into biology, pathogenic mechanisms, therapeutic approaches.
Язык: Английский
Процитировано
57
Diagnostics, Год журнала: 2022, Номер 12(9), С. 2051 - 2051
Опубликована: Авг. 24, 2022
Coronavirus disease 2019 (COVID-19) is primarily caused by various forms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants. COVID-19 characterized hyperinflammation, oxidative stress, multi-organ injury (MOI)-like lung (ALI) and distress (ARDS). Different biomarkers are used in the assessment severity including D-dimer, ferritin, lactate dehydrogenase (LDH), hypoxia-inducible factor (HIF). Interestingly, growth differentiation 15 (GDF15) has recently become a potential biomarker correlated with severity. Thus, this critical review aimed to determine association between GDF15 COVID-19. The perfect function remains not well-recognized; nevertheless, it plays vital role controlling cell growth, apoptosis inflammatory activation. Furthermore, may act as anti-inflammatory pro-inflammatory signaling diverse cardiovascular complications. release activated factors cytokines macrophage colony-stimulating (M-CSF), angiotensin II (AngII) p53. Therefore, higher expression might compensatory mechanism stabilize counteract dysregulated reactions. In conclusion, an cytokine that could be associated Increased against hyperinflammation exaggerated immune response Experimental, preclinical large-scale clinical studies warranted regard.
Язык: Английский
Процитировано
45
Biomedicines, Год журнала: 2022, Номер 10(8), С. 2032 - 2032
Опубликована: Авг. 20, 2022
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection can trigger the adaptive and innate immune responses, leading to uncontrolled inflammatory reactions associated local systematic tissue damage, along with thromboembolic disorders that may increase risk of ischemic stroke (AIS) in COVID-19 patients. The neuropilin (NRP-1) which is a co-receptor for vascular endothelial growth factor (VEGF), integrins, plexins, involved pathogenesis AIS. NRP-1 also regarded as entry SARS-CoV-2 facilitates its into brain through olfactory epithelium. cofactor binding angiotensin-converting enzyme (ACE2), since absence ACE2 reduces infectivity even presence NRP-1. Therefore, aim present study was clarify potential role patients transmit epithelium nasal cavity, different neurological disorders, therefore about 45% had manifestations. has capability attenuate neuroinflammation, blood-brain barrier (BBB) permeability, cerebral dysfunction (ED), neuronal are uncommon involvement, including Similarly, high serum level linked ED, oxidative stress, pulmonary thrombosis severe COVID-19, suggesting compensatory mechanism overcome immuno-inflammatory disorders. In conclusion, an important AIS, could be biomarker linking development AIS COVID-19. findings cannot provide final thus silico, experimental, vitro, vivo, preclinical, clinical studies recommended confirm elucidate pharmacological receptor agonists antagonists
Язык: Английский
Процитировано
40
Journal of Korean Medical Science, Год журнала: 2024, Номер 39(14)
Опубликована: Янв. 1, 2024
The global research and pharmaceutical community rapidly mobilized to develop treatments for coronavirus disease 2019 (COVID-19). Existing have been repurposed new drugs emerged. Here we summarize mechanisms clinical trials of COVID-19 therapeutics approved or in development. Two reviewers, working independently, reviewed published data vaccines drugs, as well developmental pipelines, using databases from the following organizations: United States Food Drug Administration (US-FDA), European Medicines Agency (EMA), Japanese Pharmaceutical Medical Devices (PMDA), ClinicalTrials.gov. In all, 387 were found initial review. After removing unrelated 66 selected, including 17 49 under These classified into six categories: 1) targeting viral life cycle 2) Anti-severe acute respiratory syndrome 2 Monoclonal Antibodies, 3) immunomodulators, 4) anti-coagulants, 5) COVID-19-induced neuropathy 6) other therapeutics. Among development are following: 6 cycle, 12 immunosuppression immunostimulants, HIF-PHD 3 GM-CSF 5 others. This review provides insight action, properties, indications medications.
Язык: Английский
Процитировано
8
Inflammopharmacology, Год журнала: 2022, Номер 31(1), С. 1 - 7
Опубликована: Ноя. 23, 2022
Abstract In coronavirus disease 2019 (Covid-19) era, neuroinflammation may develop due to neuronal tropism of severe acute respiratory syndrome type 2 (SARS-CoV-2) and/or associated immune activation, cytokine storm, and psychological stress. SARS-CoV-2 infection linked storm cause blood–brain barrier (BBB) injury through which activated cells can pass into the brain causing activation glial with subsequent neuroinflammation. Different therapeutic regimens were suggested alleviate Covid-19-induced Since glibenclamide has anti-inflammatory neuroprotective effects, it could be effective in mitigation infection-induced Glibenclamide is a second-generation drug from sulfonylurea family, acts by inhibiting adenosine triphosphate (ATP)-sensitive K channel regulatory subunit 1 receptor (SUR-1) pancreatic β cells. reduces BBB nod-like pyrin 3 (NLRP3) inflammasome, oxidative stress, microglial activation. Therefore, inhibition NLRP3 stress attenuate SARS-CoV-2-mediated
Язык: Английский
Процитировано
37
Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2022, Номер 396(3), С. 453 - 468
Опубликована: Дек. 3, 2022
Язык: Английский
Процитировано
28
Inflammopharmacology, Год журнала: 2022, Номер 30(6), С. 2411 - 2415
Опубликована: Сен. 30, 2022
Abstract Coronavirus disease 2019 (Covid-19) is caused by severe acute respiratory syndrome type 2 (SARS-CoV-2). Covid-19 characterized hyperinflammation, oxidative stress, and multi-organ injury (MOI) such as lung (ALI) distress (ARDS). mainly presented with manifestations; however, extra-pulmonary manifestations may also occur. Extra-pulmonary of are numerous including: neurological, cardiovascular, renal, endocrine, hematological complications. Notably, a cluster differentiation 26 (CD26) or dipeptidyl peptidase-4 (DPP-4) emerged new receptor for entry SARS-CoV-2. Therefore, DPP-4 inhibitors like sitagliptin could be effective in treating Covid-19. Hence, we aimed the present critical review to assess potential role against increased severity SARS-CoV-2 infections. Moreover, inhibit interaction between scaffolding proteins which essential endosome formation replication through attenuation inflammatory signaling pathway augmentation stromal-derived factor-1 (SDF-1) decrease pathogenesis infection possible therapeutic modality patients. In conclusion, regarded binding Inhibition these receptors inhibitor, sitagliptin, can reduce their associated activation pathways.
Язык: Английский
Процитировано
23
Clinical and Experimental Pharmacology and Physiology, Год журнала: 2023, Номер 50(5), С. 335 - 352
Опубликована: Фев. 3, 2023
Abstract Dantrolene (DTN) is a ryanodine receptor (RyR) antagonist that inhibits Ca 2+ release from stores in the sarcoplasmic reticulum. DTN mainly used management of malignant hyperthermia. RyRs are highly expressed immune cells and involved different viral infections, including severe acute respiratory syndrome coronavirus type 2 (SARS‐CoV‐2), because necessary for replication, maturation release. can inhibit proliferation SARS‐CoV‐2, indicating its potential role reducing entry pathogenesis SARS‐CoV‐2. may increase clearance SARS‐CoV‐2 promote disease 2019 (COVID‐19) recovery by shortening period infection. N‐methyl‐D‐aspartate (NMDA) mediated platelets aggregations thrombosis. Therefore, thrombosis coagulopathy COVID‐19 through suppression platelet NMDA receptors. Moreover, has neuroprotective effect against infection‐induced brain injury modulation receptors, which excitotoxicity, neuronal development neuropsychiatric disorders. In conclusion, inhibiting attenuate inflammatory disorders infection associated cardio‐pulmonary complications. DNT could be promising drug therapy COVID‐19. Preclinical clinical studies warranted this regards.
Язык: Английский
Процитировано
11
Immunity Inflammation and Disease, Год журнала: 2023, Номер 11(4)
Опубликована: Апрель 1, 2023
Coronavirus disease 2019 (Covid-19) is caused by a novel severe acute respiratory syndrome coronavirus virus type 2 (SARS-CoV-2) leading to the global pandemic worldwide. Systemic complications in Covid-19 are mainly related direct SARS-CoV-2 cytopathic effects, associated hyperinflammation, hypercytokinemia, and development of cytokine storm (CS). As well, developed due propagation oxidative thrombotic events which may progress state called (TS), respectively. In addition, inflammatory lipid storms also activation cells release bioactive lipids correspondingly. Therefore, present narrative review aimed elucidate interrelated relationship between different types mixed (MS). conclusion, infection induces various including CS, storm, TS storm. These not developing alone since there close them. MS seems be more appropriate than it develops intricate interface reactive oxygen species, proinflammatory cytokines, complement activation, coagulation disorders, activated signaling pathway.
Язык: Английский
Процитировано
11